Paradigmaváltás az emlorák kemoterápiás gyakorlatában

Translated title of the contribution: Shift in the chemotherapeutic paradigms of breast cancer

Research output: Contribution to journalArticle

Abstract

In the past decade there have been a basic shift in the general management and the chemotherapeutic practice of breast cancer. It had been demonstrated that by the adjuvant treatment of early breast cancer disease-related mortality can be substantially reduced, and could be further ameliorated by treatments individually tailored to prognosis. Anthracyclins are likely to enter into the field of premenopausal moderate, and unfavourable prognosis cases' adjuvant chemotherapy. Newer cytostatics represent unique efficiency (taxans: hepatic metastases, anthracyclin resistance) or milder and altered side-effects (anthrapirazoles, vinorelbine). High-dose chemotherapy opened new perspectives in breast cancer therapy. Initially experienced high treatment-related mortality has substantially been reduced, and significantly more eventually extremely durable remissions have been induced by delivering drug doses 5-10 times higher than conventionally applyed. As a result of the improvement of therapeutic efficiency, reduction of side-effects, and costs the indication of high-dose chemotherapy is changing and widening (adjuvant treatment of moderate and unfavourable breast cancer cases, locally advanced and inflammatory breast cancer). With the advent of supportive treatment modalities the side-effects of chemotherapy can selectively be controlled. Consequently chemotherapy can be more efficiently and safely delivered, and represents a more convenient treatment modality for the patient than a decade ago.

Original languageHungarian
Pages (from-to)112-118
Number of pages7
JournalMagyar Onkologia
Volume41
Issue number2
Publication statusPublished - 1997

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Inflammatory Breast Neoplasms
Breast Diseases
Mortality
Practice Management
Cytostatic Agents
Adjuvant Chemotherapy
Neoplasm Metastasis
Costs and Cost Analysis
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Paradigmaváltás az emlorák kemoterápiás gyakorlatában. / Kahán, Z.

In: Magyar Onkologia, Vol. 41, No. 2, 1997, p. 112-118.

Research output: Contribution to journalArticle

@article{7c47556b3eab43058b105cb1d6be0e04,
title = "Paradigmav{\'a}lt{\'a}s az emlor{\'a}k kemoter{\'a}pi{\'a}s gyakorlat{\'a}ban",
abstract = "In the past decade there have been a basic shift in the general management and the chemotherapeutic practice of breast cancer. It had been demonstrated that by the adjuvant treatment of early breast cancer disease-related mortality can be substantially reduced, and could be further ameliorated by treatments individually tailored to prognosis. Anthracyclins are likely to enter into the field of premenopausal moderate, and unfavourable prognosis cases' adjuvant chemotherapy. Newer cytostatics represent unique efficiency (taxans: hepatic metastases, anthracyclin resistance) or milder and altered side-effects (anthrapirazoles, vinorelbine). High-dose chemotherapy opened new perspectives in breast cancer therapy. Initially experienced high treatment-related mortality has substantially been reduced, and significantly more eventually extremely durable remissions have been induced by delivering drug doses 5-10 times higher than conventionally applyed. As a result of the improvement of therapeutic efficiency, reduction of side-effects, and costs the indication of high-dose chemotherapy is changing and widening (adjuvant treatment of moderate and unfavourable breast cancer cases, locally advanced and inflammatory breast cancer). With the advent of supportive treatment modalities the side-effects of chemotherapy can selectively be controlled. Consequently chemotherapy can be more efficiently and safely delivered, and represents a more convenient treatment modality for the patient than a decade ago.",
author = "Z. Kah{\'a}n",
year = "1997",
language = "Hungarian",
volume = "41",
pages = "112--118",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Paradigmaváltás az emlorák kemoterápiás gyakorlatában

AU - Kahán, Z.

PY - 1997

Y1 - 1997

N2 - In the past decade there have been a basic shift in the general management and the chemotherapeutic practice of breast cancer. It had been demonstrated that by the adjuvant treatment of early breast cancer disease-related mortality can be substantially reduced, and could be further ameliorated by treatments individually tailored to prognosis. Anthracyclins are likely to enter into the field of premenopausal moderate, and unfavourable prognosis cases' adjuvant chemotherapy. Newer cytostatics represent unique efficiency (taxans: hepatic metastases, anthracyclin resistance) or milder and altered side-effects (anthrapirazoles, vinorelbine). High-dose chemotherapy opened new perspectives in breast cancer therapy. Initially experienced high treatment-related mortality has substantially been reduced, and significantly more eventually extremely durable remissions have been induced by delivering drug doses 5-10 times higher than conventionally applyed. As a result of the improvement of therapeutic efficiency, reduction of side-effects, and costs the indication of high-dose chemotherapy is changing and widening (adjuvant treatment of moderate and unfavourable breast cancer cases, locally advanced and inflammatory breast cancer). With the advent of supportive treatment modalities the side-effects of chemotherapy can selectively be controlled. Consequently chemotherapy can be more efficiently and safely delivered, and represents a more convenient treatment modality for the patient than a decade ago.

AB - In the past decade there have been a basic shift in the general management and the chemotherapeutic practice of breast cancer. It had been demonstrated that by the adjuvant treatment of early breast cancer disease-related mortality can be substantially reduced, and could be further ameliorated by treatments individually tailored to prognosis. Anthracyclins are likely to enter into the field of premenopausal moderate, and unfavourable prognosis cases' adjuvant chemotherapy. Newer cytostatics represent unique efficiency (taxans: hepatic metastases, anthracyclin resistance) or milder and altered side-effects (anthrapirazoles, vinorelbine). High-dose chemotherapy opened new perspectives in breast cancer therapy. Initially experienced high treatment-related mortality has substantially been reduced, and significantly more eventually extremely durable remissions have been induced by delivering drug doses 5-10 times higher than conventionally applyed. As a result of the improvement of therapeutic efficiency, reduction of side-effects, and costs the indication of high-dose chemotherapy is changing and widening (adjuvant treatment of moderate and unfavourable breast cancer cases, locally advanced and inflammatory breast cancer). With the advent of supportive treatment modalities the side-effects of chemotherapy can selectively be controlled. Consequently chemotherapy can be more efficiently and safely delivered, and represents a more convenient treatment modality for the patient than a decade ago.

UR - http://www.scopus.com/inward/record.url?scp=84882724949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882724949&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 112

EP - 118

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -